Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neurogene Inc. (NGNE : NSDQ)

• Company Description    Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK. Number of Employees: 131

• Price / Volume Information    Yesterday's Closing Price: $34.90 Daily Weekly Monthly 20 Day Moving Average: 321,385 shares Shares Outstanding: 15.80 (millions) Market Capitalization: $551.49 (millions) Beta: 1.68 52 Week High: $43.66 52 Week Low: $15.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.76% 13.92% 12 Week 33.77% 30.10% Year To Date 69.42% 59.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 535 W 24TH STREET 5TH FLOOR - NEW YORK,NY 10011 USA ph: 855-508-3568 fax: 778-331-4486 neurogene@argotpartners.com http://www.neurogene.com

• General Corporate Information    Officers Rachel McMinn - Chief Executive Officer Christine Mikail - President and Chief Financial Officer Robert Baffi - Director Cory Freedland - Director Sarah B. Noonberg - Director Peer Information Neurogene Inc. (CORR.) Neurogene Inc. (RSPI) Neurogene Inc. (CGXP) Neurogene Inc. (BGEN) Neurogene Inc. (GTBP) Neurogene Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64135M105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 15.80 Most Recent Split Date: 12.00 (0.25:1) Beta: 1.68 Market Capitalization: $551.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.63 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -28.70% vs. Previous Quarter: -24.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -37.88 12/31/25 - -32.99 ROA 06/30/26 - - 03/31/26 - -34.70 12/31/25 - -30.39 Current Ratio 06/30/26 - - 03/31/26 - 13.08 12/31/25 - 16.56 Quick Ratio 06/30/26 - - 03/31/26 - 13.08 12/31/25 - 16.56 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 15.23 12/31/25 - 17.10 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©